Evidence map›Paper›PMID 38726290›Full record

ArticleAmerican journal of cancer research2024

SSH3 promotes pancreatic cancer proliferation and migration by activating the notch signaling pathway.

Chengxiao Yang, Gang Quan, Shihang Zhang, Jianxin Jiang

Abstract read
In one paragraph

Article in American journal of cancer research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Chengxiao YangDepartment of Hepatobiliary, Pancreatic and Splenic Surgery, The Tenth Affiliated Hospital, Southern Medical University (Dongguan People's Hospital) Dongguan, Guangdong, China.
Gang QuanDepartment of Hepatobiliary, Pancreatic and Splenic Surgery, The Tenth Affiliated Hospital, Southern Medical University (Dongguan People's Hospital) Dongguan, Guangdong, China.
Shihang ZhangDepartment of Hepatobiliary, Pancreatic and Splenic Surgery, The Tenth Affiliated Hospital, Southern Medical University (Dongguan People's Hospital) Dongguan, Guangdong, China.
Jianxin JiangDepartment of Hepatobiliary, Pancreatic and Splenic Surgery, The Tenth Affiliated Hospital, Southern Medical University (Dongguan People's Hospital) Dongguan, Guangdong, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recent studies have indicated that the dual-specificity phosphatases (DUSP) family may play a role in the advancement of pancreatic cancer. Exploring the role of the DUSP family in pancreatic cancer development and discovering novel therapeutic targets are crucial for pancreatic cancer therapy. A critical subset of 20 genes exhibiting differential expression was identified, with particular emphasis on four key genes: DUSP10, PTP4A2, SSH3, and CDKN3 by multivariate Cox proportional hazards analysis. These genes were integral to developing a novel risk model for PC, which has been independently validated as a prognostic factor for patients. To provide help for clinical treatment, we performed tumor immune analysis and predicted potential chemical drugs. Notably, our research unveiled elevated expression levels of SSH3 in human PC cells and tissues. Intriguingly, SSH3 expression correlates with the patient grade, staging, and T stage in PC. Additional studies reveal SSH3's role in enhancing PC cell proliferation and migration, intricately linked to the activation of the Notch signaling pathway. These insights provide a deeper understanding of PC pathophysiology and pave the way for novel therapeutic interventions.

Indexed as

DUSP familypancreatic cancerprognostic predictionSlingshot protein phosphatase 3TCGA

Identifiers

PMID38726290
PMCPMC11076266

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.